What Is New - Spondyloarthritis and Psoriatic Arthritis
Take a look at our 'What is new' highlights in spondyloarthritis and psoriatic arthritis!
May 2023
"Sex-Specific Differences in Patients With Psoriatic Arthritis: A Systematic Review"
Why WIN?
This systematic review of published literature about real-world populations may be the first of its kind to capture this breadth of PsA disease aspects compared by sex. It suggests that some clinical characteristics in PsA differ between the sexes. Women report worse scores across a range of patient reported outcomes, whereas men respond better to treatment. Clinician awareness of the potential differences in clinical characteristics and patients’ perceptions of their disease may help to improve patient outcomes.
Do you believe that there is a need for a personalized care according to sex differences in psoriatic arthritis?
Agree / Disagree
Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET
Link to original article: https://www.jrheum.org/content/jrheum/50/4/488.full.pdf
April 2023
"Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: an analysis of the German register RABBIT-SpA"
Why WIN?
Axial manifestation in PsA is common but there is no consensus in the definition of axPsA. This study shows that patients with axPsA are different from ‘typical’ axSpA, even if axSpA patients with psoriasis are used as a comparator. The observed differences between axPsA and axSpA in this cohort were similar regardless of whether a clinical or an imaging-based definition of axial involvement was used. Extrapolation of the evidence derived from trials in axSpA patients to axial manifestations in PsA should be done with caution.
Do you discuss about diet with your patients with spondyloarthritis as part of routine care?
yes / no
Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET
March 2023
"The impact of diet on disease activity in spondyloarthritis: A systematic literature review"
Why WINS?
Diet, as a non-pharmacological measure, is recognized as a core part of the management of spondyloarthritis (SpA), but data on the topic is scarce. This review highlights the lack of high-quality studies about the effect of dietary regimens/supplement on SpA disease activity, as well as the heterogeneity of the interventions and the outcomes studied so far. Further research is warranted as this might impact quality of care and patient outcomes in SpA.
Do you discuss about diet with your patients with spondyloarthritis as part of routine care?
yes / no
Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET
February 2023
" Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumor necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE) "
Why WINS?
The data from the BE-OPTIMAL and BE-COMPLETE phase 3 trials of bimekizumab as a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17 A AND F in PsA patients are really promising and especially the response rates in TNF-i inadequate responders from the BE-COMPLETE study are indicating a new important therapeutic option, especially in those patients that are usually complicated to manage in our clinical routine. This in combination with the promising data from dedicated RCTs in skin psoriasis are pointing out the potential of this new mode of action
Interactive question
Will the availability of dual IL-17 A&F inhibition change your clinical practice of treating patients with psoriatic diseases?
Yes, this might become my preferred choice for PsO/PsA patients
No, but still good to have as an alternative option
Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET
Jan 2023
" Alterations in the cutaneous microbiome of patients with psoriasis and psoriatic arthritis reveal similarities between non-lesional and lesional skin "
Why WINS?
The ´holy-grail` of research in psoriatic diseases is how to identify those patients with skin psoriasis (PsO), that will develop musculoskeletal manifestations of a Psoriatic Arthritis (PsA) over time. This fascinating study from the working group of Jose Scher found differences in the skin microbiome between healthy individuals and patients with psoriatic diseases. Furthermore, differences in the cutaneous microbiota between PsO and PsA patients might open new opportunities to identify PsO patients at risk for developing musculoskeletal involvement
Interactive question
Is the identification of PsO patients at risk for developing PsA clinically relevant from your perspective?
Yes, as this could lead to an intisified treatment approach in PsO patients
No, as treatment will still be initiated when clinical musculoskeletal symptoms are evident
Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET
December 2022
"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update"
Why WIN?
Here you can find the evidence based update of the international management recommendations for axial SpA of ASAS and EULAR. Get updated about the newest advances regarding all related topics of the management of your clinical routine taking care of patients with axial SpA. From diagnosis, disease activity assessment, patient education to pharmacological as well as non-pharmacological interventions!
Interactive question
What is the most important point for you on the research agenda of axial SpA?
-
-
New treatment targets
-
Disease specific biomarkers
-
Comorbidities
-
How to treat from target?
-
Something else. Please explain in the comments
-
Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET
November 2022
"Deep learning algorithms for magnetic resonance imaging of inflammatory sacroiliitis in axial spondyloarthritis"
Why WIN?
Deep learning segmentation is a subset of artificial intelligence (AI) machine learning, and it currently has wide applications in various areas of medical imaging analysis. A deep learning segmentation algorithm prototype was developed for detection of MRI sacroiliitis. Performance of the AI algorithm was similar to that of the radiologist, and superior to that of the rheumatologist.
Interactive question
Do you consider that artificial intelligence machine learning algorithms may be utilized for the diagnosis of SpA and the assessment of disease activity?
Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET
"Diagnostic evaluation of the sacroiliac joints for axial spondyloarthritis: should MRI replace radiography?"
Why WIN?
The diagnosis of axial SpA is strongly imaging based. The most recent EULAR Recommmendations for Imaging in SpA suggest conventional x-ray of the sacroiliac joints (SIJs) as the primary imaging modality in suspected cases of axSpA. Recent evidence suggest clear superiority of MRI over x-ray also for the assessment of structural changes of the SIJs. This lead to the viewpoint just published in ARD. This should trigger a discussion within the community taking costs, access in different settings/geographical regions, radioation exposure and ability for early diagnosis of axSpA into account.
Interactive question
What is your preferred first imaging modality in patients with suspicion of axSpA?
a) x-ray of the SIJs
b) MRI of the SIJs
c) None of the above. Please explain in the comments
Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET
